Background and aim Narcolepsy is an uncommon hypothalamic disorder of presumed
autoimmune origin that usually requires lifelong treatment. This paper aims to provide …

Excessive daytime sleepiness (EDS) is a public health issue. However, it remains largely
undervalued, scarcely diagnosed, and poorly supported. Variations in the definition of EDS …

Narcolepsy type 1 (NT1) is a sleep disorder caused by a loss of orexinergic neurons.
Narcolepsy type 2 (NT2) is heterogeneous; affected individuals typically have normal orexin …

Objective Solriamfetol (JZP‐110) is a selective dopamine and norepinephrine reuptake
inhibitor with wake‐promoting effects. This phase 3 study (NCT02348593) evaluated the …

This article addresses the clinical presentation, diagnosis, pathophysiology and
management of narcolepsy type 1 and 2, with a focus on recent findings. A low level of …

Summary Narcolepsy type 1 (NT1) is a lifelong disorder of sleep-wake dysregulation defined
by clinical symptoms, neurophysiological findings, and low hypocretin levels. Besides a role …

Abstract Narcolepsy type 1 (NT1) and type 2 (NT2), also known as narcolepsy with and
without cataplexy, are sleep disorders that benefited from major scientific advances over the …

Narcolepsy type 1 (NT1) is a chronic orphan disorder, caused by the selective and
irreversible loss of hypocretin/orexin (ORX) neurons, by a probable autoimmune process …

Rationale: Excessive daytime sleepiness is a common disabling symptom in obstructive
sleep apnea syndrome. Objectives: To evaluate the efficacy and safety of pitolisant, a …

Narcolepsy is a chronic, debilitating neurological disorder of sleep-wake state instability.
This instability underlies all narcolepsy symptoms, including excessive daytime sleepiness …